Neodiset (Calcifediol Monohydrate)

Calcifediol is the 25‑hydroxy form of vitamin D3. After oral absorption, it circulates as a pre‑hormone and is converted in the kidneys to the active hormone calcitriol. Calcitriol binds the vitamin D receptor, increasing intestinal absorption of calcium and phosphate and influencing bone remodeling.

The appropriate dose of Neodiset is determined by a qualified prescriber based on the patient’s serum 25‑hydroxyvitamin D level, renal function, and clinical condition. Dosing may vary widely, and clinicians tailor the regimen to achieve target vitamin D status while avoiding excess calcium.

Safety data for calcifediol during pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and only under medical supervision. Patients should discuss their individual situation with a healthcare professional.

To request Neodiset, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any temperature control) and necessary import documentation.

Neodiset (calcifediol) is a 25‑hydroxyvitamin D3, which is more rapidly converted to the active form than cholecalciferol (vitamin D3) and does not require hepatic activation. This can result in a faster rise in serum 25‑hydroxyvitamin D levels, making it useful in patients with impaired liver function or those needing a quicker therapeutic effect.

Neodiset should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, excessive heat, and direct sunlight to maintain stability and potency throughout its shelf life.

Neodiset is taken orally, usually as a tablet or capsule, with or without food as directed by the prescribing clinician. The exact administration instructions, including timing and whether to take with meals, are provided by the healthcare professional based on individual patient needs.

The most serious adverse events involve excessive calcium levels (hypercalcemia), which can cause cardiac arrhythmias, kidney stones, or soft‑tissue calcification. Severe hyperphosphatemia and renal impairment may also occur, especially in patients with underlying kidney disease or when combined with high calcium intake.

Neodiset should be avoided in patients with known hypercalcemia, severe renal failure, active granulomatous diseases (e.g., sarcoidosis), or a documented hypersensitivity to calcifediol or any excipients. Clinicians must assess individual risk factors before initiating therapy.